HK1191645A1 - -甲氧基-吡啶- -基衍生物 - Google Patents

-甲氧基-吡啶- -基衍生物

Info

Publication number
HK1191645A1
HK1191645A1 HK14104850.5A HK14104850A HK1191645A1 HK 1191645 A1 HK1191645 A1 HK 1191645A1 HK 14104850 A HK14104850 A HK 14104850A HK 1191645 A1 HK1191645 A1 HK 1191645A1
Authority
HK
Hong Kong
Prior art keywords
pyridin
methoxy
derivatives
Prior art date
Application number
HK14104850.5A
Other languages
English (en)
Inventor
Martin Bolli
Cyrille Lescop
Boris Mathys
Keith Morrison
Claus Mueller
Oliver Nayler
Beat Steiner
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45607310&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1191645(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of HK1191645A1 publication Critical patent/HK1191645A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
HK14104850.5A 2011-01-19 2014-05-23 -甲氧基-吡啶- -基衍生物 HK1191645A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2011050241 2011-01-19
PCT/IB2012/050241 WO2012098505A1 (en) 2011-01-19 2012-01-18 2-methoxy-pyridin-4-yl derivatives

Publications (1)

Publication Number Publication Date
HK1191645A1 true HK1191645A1 (zh) 2014-08-01

Family

ID=45607310

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14104850.5A HK1191645A1 (zh) 2011-01-19 2014-05-23 -甲氧基-吡啶- -基衍生物

Country Status (28)

Country Link
US (1) US9133179B2 (zh)
EP (1) EP2665720B1 (zh)
JP (1) JP5859570B2 (zh)
KR (1) KR101869120B1 (zh)
CN (1) CN103313981B (zh)
AR (1) AR084883A1 (zh)
AU (1) AU2012208325B2 (zh)
BR (1) BR112013017923B1 (zh)
CA (1) CA2818470C (zh)
CL (1) CL2013002056A1 (zh)
CY (1) CY1116657T1 (zh)
DK (1) DK2665720T3 (zh)
ES (1) ES2544086T3 (zh)
HK (1) HK1191645A1 (zh)
HR (1) HRP20150919T1 (zh)
HU (1) HUE026012T2 (zh)
IL (1) IL227509A0 (zh)
MA (1) MA34910B1 (zh)
MX (1) MX350009B (zh)
MY (1) MY163185A (zh)
PL (1) PL2665720T3 (zh)
PT (1) PT2665720E (zh)
SG (1) SG191742A1 (zh)
SI (1) SI2665720T1 (zh)
TW (1) TWI546300B (zh)
UA (1) UA109804C2 (zh)
WO (1) WO2012098505A1 (zh)
ZA (1) ZA201306193B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2649475T3 (es) 2013-03-15 2018-01-12 Idorsia Pharmaceuticals Ltd Derivados de piridin-4-ilo
EP2990055B1 (en) 2013-04-26 2019-06-05 Kyoto University Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it
CN105760707B (zh) * 2014-12-18 2018-07-31 中国科学院大连化学物理研究所 细胞基因翻译过程建模方法
SG11201708794PA (en) 2015-05-20 2017-12-28 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
CN107382965A (zh) * 2017-08-14 2017-11-24 河南科技大学第附属医院 具有抗肿瘤活性的新型s1p‑1受体激动剂药物分子的合成方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31990A (en) 1968-04-26 1974-05-16 Chinoin Gyogyszer Es Vegyeszet Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same
WO1991015583A1 (en) 1990-04-05 1991-10-17 The American National Red Cross A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
AU653957B2 (en) 1990-09-20 1994-10-20 Merrell Dow Pharmaceuticals Inc. 1-aryl-3-pyridinyl-2-propene-1-ones
DE4429465A1 (de) 1994-08-19 1996-02-22 Bayer Ag Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde
JP2002505868A (ja) 1998-03-09 2002-02-26 スミスクライン・ビーチャム・コーポレイション ヒトEDG−1cポリヌクレオチドおよびポリペプチドおよびその使用法
DE19904389A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
CA2381975A1 (en) 1999-08-19 2001-02-22 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1679313A3 (en) 2001-02-21 2006-08-16 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
DE60330047D1 (en) 2002-01-18 2009-12-24 Merck & Co Inc "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
DE60329073D1 (de) 2002-01-18 2009-10-15 Merck & Co Inc Edg-rezeptoragonisten
CA2488117A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
DE10237883A1 (de) 2002-08-19 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
AU2003279915A1 (en) 2002-10-15 2004-05-04 Merck And Co., Inc. Process for making azetidine-3-carboxylic acid
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
AU2004240586A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
WO2005014525A2 (en) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
CA2539438A1 (en) 2003-10-01 2005-04-14 Merck And Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
EP1697333A4 (en) 2003-12-17 2009-07-08 Merck & Co Inc 3,4-DISUSBSTITUTED PROPANOIC CARBOXYLATES AS S1P RECEPTOR AGONISTS (EDG)
EP1758579A1 (en) 2004-05-29 2007-03-07 7TM Pharma A/S Crth2 receptor ligands for medicinal uses
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
CN101043887A (zh) 2004-10-22 2007-09-26 默克公司 用作s1p受体激动剂的2-(芳基)氮杂环甲基羧酸酯、磺酸酯、膦酸酯、次膦酸酯和杂环化合物
PL1826197T3 (pl) 2004-12-13 2012-06-29 Ono Pharmaceutical Co Pochodna kwasu aminokarboksylowego i jej zastosowanie lecznicze
US7605269B2 (en) 2005-03-23 2009-10-20 Actelion Pharmaceuticals Ltd. Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists
PT1863787E (pt) 2005-03-23 2011-07-29 Actelion Pharmaceuticals Ltd Derivados de benzo(c)tiofenos hidrogenados como imunomoduladores
WO2006100635A2 (en) 2005-03-23 2006-09-28 Actelion Pharmaceuticals Ltd Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
KR20080013886A (ko) 2005-04-05 2008-02-13 파마코페이아, 인코포레이티드 면역억제용 퓨린 및 이미다조피리딘 유도체
CN101203512A (zh) 2005-04-22 2008-06-18 第一三共株式会社 杂环化合物
WO2006114400A1 (en) 2005-04-26 2006-11-02 Neurosearch A/S Novel oxadiazole derivatives and their medical use
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
WO2006135694A2 (en) 2005-06-10 2006-12-21 Acadia Pharmaceuticals Inc. Uii-modulating compounds and their use
CA2612661A1 (en) 2005-06-24 2006-12-28 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives
CN101203220A (zh) 2005-06-28 2008-06-18 阿斯利康(瑞典)有限公司 新用途
AR057894A1 (es) 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
TWI404706B (zh) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
JP5063615B2 (ja) 2006-01-24 2012-10-31 アクテリオン ファーマシューティカルズ リミテッド 新規ピリジン誘導体
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
JP2009527501A (ja) 2006-02-21 2009-07-30 ユニバーシティ オブ バージニア パテント ファンデーション S1p受容体アゴニストとしてのフェニル−シクロアルキル誘導体およびフェニル−複素環誘導体
MX2008013990A (es) 2006-05-09 2009-01-29 Pfizer Prod Inc Derivados de cicloalquilamino acidos.
ES2400533T3 (es) * 2006-09-07 2013-04-10 Actelion Pharmaceuticals Ltd. Derivados de piridin 4-ilo como agentes inmunomoduladores
AR061841A1 (es) 2006-09-07 2008-09-24 Actelion Pharmaceuticals Ltd Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
NZ576059A (en) 2006-09-08 2012-03-30 Actelion Pharmaceuticals Ltd Pyridin-3-yl derivatives as immunomodulating agents
AU2007298593A1 (en) 2006-09-21 2008-03-27 Actelion Pharmaceuticals Ltd Phenyl derivatives and their use as immunomodulators
WO2008037476A1 (en) 2006-09-29 2008-04-03 Novartis Ag Oxadiazole derivatives with anti-inflammatory and immunosuppressive properties
JP2008120794A (ja) 2006-10-16 2008-05-29 Daiichi Sankyo Co Ltd ヘテロ環化合物を含有する医薬組成物
US20110207704A1 (en) 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
BRPI0720043A2 (pt) 2006-12-15 2014-01-07 Abbott Lab Composto oxadiazol
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
SI2125797T1 (sl) 2007-03-16 2014-03-31 Actelion Pharmaceuticals Ltd. Derivati amino-piridina kot agonisti receptorja s1p1/edg1
US8598208B2 (en) 2007-08-17 2013-12-03 Actelion Pharmaceuticals Ltd. Pyridine derivatives as S1P1/EDG1 receptor modulators
BRPI0817597A2 (pt) 2007-10-04 2015-04-07 Merck Serono Sa Compostos de diarila de oxadiazol, processo para sua preparação, composições farmacêuticas e kit compreendendo os mesmos, bem como seus usos
KR20100075608A (ko) 2007-10-04 2010-07-02 메르크 세로노 에스. 에이. 옥사다이졸 유도체
AR069146A1 (es) 2007-11-01 2009-12-30 Actelion Pharmaceuticals Ltd Derivados de pirimidina, composicion farmaceutica que los comprende y el uso de esta para el tratamiento de enfermedades relacionadas con la activacion del sistema inmunitario.
CA2703987A1 (en) 2007-11-08 2009-05-14 Pfizer Inc. Cyclobutyl carboxylic acid derivatives
MX2010005889A (es) 2007-12-10 2010-06-22 Actelion Pharmaceuticals Ltd Derivados de tiofeno como agonistas de s1p1/edg1.
ATE531711T1 (de) * 2007-12-18 2011-11-15 Arena Pharm Inc Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate
EP2262799B1 (en) 2008-03-06 2012-07-04 Actelion Pharmaceuticals Ltd. Pyridine compounds
JP2011513385A (ja) 2008-03-06 2011-04-28 アクテリオン ファーマシューティカルズ リミテッド 新規なピリミジン−ピリジン誘導体
BRPI0910288A2 (pt) 2008-03-07 2019-09-24 Actelion Pharmaceuticals Ltd composto de derivados de aminometil benzeno, composição farmacêutica que compreende esse composto e uso do mesmo.
WO2009109872A1 (en) 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Pyridin-2-yl derivatives as immunomodulating agents
EP2291080B1 (en) 2008-05-14 2015-08-19 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors
AR077227A1 (es) 2009-06-26 2011-08-10 Glaxo Group Ltd Compuesto de acido aril/ heteroaril- sustituido carboxilico, su uso para fabricar un medicamento util el tratamiento de afecciones o trastornos mediados por receptores s1p1, tales como esclerosis multiple y composicion farmaceutica que lo comprende
RU2547098C2 (ru) 2009-07-16 2015-04-10 Актелион Фармасьютиклз Лтд Производные пиридин-4-ила

Also Published As

Publication number Publication date
CA2818470C (en) 2019-03-05
MX350009B (es) 2017-08-23
CA2818470A1 (en) 2012-07-26
US20130303514A1 (en) 2013-11-14
AU2012208325A1 (en) 2013-09-05
BR112013017923B1 (pt) 2021-08-10
KR101869120B1 (ko) 2018-06-19
HUE026012T2 (en) 2016-05-30
PL2665720T3 (pl) 2015-11-30
MX2013007726A (es) 2013-08-09
EP2665720A1 (en) 2013-11-27
DK2665720T3 (en) 2015-07-13
MA34910B1 (fr) 2014-02-01
JP5859570B2 (ja) 2016-02-10
NZ614367A (en) 2015-02-27
RU2013138285A (ru) 2015-02-27
KR20140014128A (ko) 2014-02-05
AU2012208325B2 (en) 2016-12-22
TWI546300B (zh) 2016-08-21
CY1116657T1 (el) 2018-04-04
HRP20150919T1 (hr) 2015-09-25
BR112013017923A8 (pt) 2017-12-26
ES2544086T3 (es) 2015-08-27
US9133179B2 (en) 2015-09-15
ZA201306193B (en) 2016-07-27
BR112013017923A2 (pt) 2017-03-21
SI2665720T1 (sl) 2015-08-31
CL2013002056A1 (es) 2013-12-27
UA109804C2 (xx) 2015-10-12
TW201309681A (zh) 2013-03-01
CN103313981B (zh) 2016-05-11
WO2012098505A1 (en) 2012-07-26
PT2665720E (pt) 2015-09-16
CN103313981A (zh) 2013-09-18
EP2665720B1 (en) 2015-06-10
AR084883A1 (es) 2013-07-10
SG191742A1 (en) 2013-08-30
JP2014502994A (ja) 2014-02-06
MY163185A (en) 2017-08-15
IL227509A0 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
DK3424953T3 (en) Terapeutiske antistoffer
SG10201601802YA (en) Dispiropyrrolidine derivatives
ZA201401884B (en) New dihydroquinoline-2-one derivatives
GB201109414D0 (en) Diathermy -ionisation technique
IL247637B (en) History of heteroaryl piperidine
IL231950B (en) Aryl-quinoline derivatives
AP2014007621A0 (en) 2-Thiopyrimidinones
EP2721029A4 (en) IMIDAZOPYRIDIN-2-ONE DERIVATIVES
HK1191645A1 (zh) -甲氧基-吡啶- -基衍生物
IL233001A0 (en) New iso-ergoline histories
DK2770906T3 (en) Applanationstonometer
SI2766342T1 (sl) Derivati fenil-gvanidina
ZA201308049B (en) 3-ureidoisoquinolin-8-yl derivatives
GB2512771B (en) Ablutionary fitting
ZA201209319B (en) Cyclopropyl-indole derivatives
AU4540P (en) BUNNAN Baloskion tetraphyllum
AU5171P (en) Sunparamiho Mandevilla xamabilis
AU5031P (en) BESYS Beschorneria yuccoides
AU5026P (en) Goldstrike Agapanthus inapertus
GB201110793D0 (en) Easy carry
AP00723S1 (en) Autorickshaw
AU2011303V (en) Silverado Dianella tasmanica
AU339857S (en) Orchidometer
AU338110S (en) Barstool
AU338420S (en) Kettlebell

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200121